Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 85 to 89 of 89 entries
Sorted by: Best Match Show Resources per page
Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus.

World journal of clinical cases

Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M.
PMID: 26989674
World J Clin Cases. 2016 Mar 16;4(3):88-93. doi: 10.12998/wjcc.v4.i3.88.

The standard antiviral therapy for dialysis patients infected with hepatitis C virus (HCV) is (pegylated) interferon monotherapy, but its efficacy is insufficient. Oral direct-acting antiviral agents (DAAs) have recently been developed for chronic hepatitis C patients. However, some DAAs...

Cite
Sato K, Yamazaki Y, Ohyama T, et al. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases. 2016;4(3):88-93doi: 10.12998/wjcc.v4.i3.88.
Sato, K., Yamazaki, Y., Ohyama, T., Kobayashi, T., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2016). Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World journal of clinical cases, 4(3), 88-93. https://doi.org/10.12998/wjcc.v4.i3.88
Sato, Ken, et al. "Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus." World journal of clinical cases vol. 4,3 (2016): 88-93. doi: https://doi.org/10.12998/wjcc.v4.i3.88
Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases. 2016 Mar 16;4(3):88-93. doi: 10.12998/wjcc.v4.i3.88. PMID: 26989674; PMCID: PMC4792170.
Copy Download .nbib Format: NLM
A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir.

Case reports in gastroenterology

Tarao K, Sato A.
PMID: 29430226
Case Rep Gastroenterol. 2017 Nov 29;11(3):736-741. doi: 10.1159/000484135. eCollection 2017.

Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. Ombitasvir/paritaprevir/ritonavir was also recommended as a therapy for...

Cite
Tarao K, Sato A. A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir. Case Rep Gastroenterol. 2017;11(3):736-741doi: 10.1159/000484135.
Tarao, K., & Sato, A. (2017). A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir. Case reports in gastroenterology, 11(3), 736-741. https://doi.org/10.1159/000484135
Tarao, Kazuo, and Sato, Akira. "A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir." Case reports in gastroenterology vol. 11,3 (2017): 736-741. doi: https://doi.org/10.1159/000484135
Tarao K, Sato A. A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir. Case Rep Gastroenterol. 2017 Nov 29;11(3):736-741. doi: 10.1159/000484135. eCollection 2017. PMID: 29430226; PMCID: PMC5803708.
Copy Download .nbib Format: NLM
Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C.

Abdominal radiology (New York)

Li A, Wu J, Cheng J, Feng C, Liu W, Li Y, Rao H, Huang R, Zhou G, Hong N, Wang Y.
PMID: 34664096
Abdom Radiol (NY). 2021 Oct 18; doi: 10.1007/s00261-021-03316-0. Epub 2021 Oct 18.

PURPOSE: To assess liver necroinflammation in HCV patients undergone antiviral therapy by Gd-EOB-DTPA-enhanced MRI with histopathologic analyses as reference.METHODS: HCV patients were enrolled in this prospective study before antiviral treatment between 09-2016 and 07-2017. Unenhanced MR, Gd-EOB-DTPA-enhanced MR, and...

Cite
Li A, Wu J, Cheng J, et al. Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C. Abdom Radiol (NY). 2021;doi: 10.1007/s00261-021-03316-0.
Li, A., Wu, J., Cheng, J., Feng, C., Liu, W., Li, Y., Rao, H., Huang, R., Zhou, G., Hong, N., & Wang, Y. (2021). Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C. Abdominal radiology (New York), . https://doi.org/10.1007/s00261-021-03316-0
Li, Anqi, et al. "Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C." Abdominal radiology (New York) vol. (2021). doi: https://doi.org/10.1007/s00261-021-03316-0
Li A, Wu J, Cheng J, Feng C, Liu W, Li Y, Rao H, Huang R, Zhou G, Hong N, Wang Y. Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C. Abdom Radiol (NY). 2021 Oct 18; doi: 10.1007/s00261-021-03316-0. Epub 2021 Oct 18. PMID: 34664096.
Copy Download .nbib Format: NLM
Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents.

Annals of clinical biochemistry

Ishida H, Takemura M, Suetsugu A, Naiki T, Tanaka T, Eiichi T, Serrero G, Matsunami H, Yamamoto Y, Saito K.
PMID: 34284614
Ann Clin Biochem. 2021 Nov;58(6):605-613. doi: 10.1177/00045632211036723. Epub 2021 Aug 11.

BACKGROUND: Progranulin (GP88) is an 88-kDa glycoprotein growth factor with important biological effects in tumorigenesis and tumour survival. We investigated the usefulness of measuring serum GP88 concentrations as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis...

Cite
Ishida H, Takemura M, Suetsugu A, et al. Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents. Ann Clin Biochem. 2021;58(6):605-613doi: 10.1177/00045632211036723.
Ishida, H., Takemura, M., Suetsugu, A., Naiki, T., Tanaka, T., Eiichi, T., Serrero, G., Matsunami, H., Yamamoto, Y., & Saito, K. (2021). Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents. Annals of clinical biochemistry, 58(6), 605-613. https://doi.org/10.1177/00045632211036723
Ishida, Hidekazu, et al. "Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents." Annals of clinical biochemistry vol. 58,6 (2021): 605-613. doi: https://doi.org/10.1177/00045632211036723
Ishida H, Takemura M, Suetsugu A, Naiki T, Tanaka T, Eiichi T, Serrero G, Matsunami H, Yamamoto Y, Saito K. Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents. Ann Clin Biochem. 2021 Nov;58(6):605-613. doi: 10.1177/00045632211036723. Epub 2021 Aug 11. PMID: 34284614.
Copy Download .nbib Format: NLM
Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals.

Journal of the Chinese Medical Association : JCMA

Su PS, Su CW, Wu SH, Wei TH, Chu CJ, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC.
PMID: 33871393
J Chin Med Assoc. 2021 May 01;84(5):465-471. doi: 10.1097/JCMA.0000000000000528.

BACKGROUND: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection is common because the two pathogens share their transmission route. Studies have suggested that coinfection is associated with accelerated hepatic fibrosis, increased hepatic decompensation, and hepatocellular carcinoma development....

Cite
Su PS, Su CW, Wu SH, et al. Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. J Chin Med Assoc. 2021;84(5):465-471doi: 10.1097/JCMA.0000000000000528.
Su, P. S., Su, C. W., Wu, S. H., Wei, T. H., Chu, C. J., Lin, C. C., Lee, S. D., Wang, Y. J., Lee, F. Y., Huang, Y. H., & Hou, M. C. (2021). Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. Journal of the Chinese Medical Association : JCMA, 84(5), 465-471. https://doi.org/10.1097/JCMA.0000000000000528
Su, Pin-Shuo, et al. "Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals." Journal of the Chinese Medical Association : JCMA vol. 84,5 (2021): 465-471. doi: https://doi.org/10.1097/JCMA.0000000000000528
Su PS, Su CW, Wu SH, Wei TH, Chu CJ, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. J Chin Med Assoc. 2021 May 01;84(5):465-471. doi: 10.1097/JCMA.0000000000000528. PMID: 33871393.
Copy Download .nbib Format: NLM
Showing 85 to 89 of 89 entries